Neuralink Confirms First Human Brain Implant

Neuralink Implants Chip in Human: "Recovering Well"

"Neuralink in a human maybe this month or next. Monkeys love it." That is how the conversation started. And that is how its first phase ended: "The first human received an implant from @Neuralink yesterday and is recovering well. Initial results show promising neuron spike detection," wrote Elon Musk. Between the promise and the statement lies a real patient, **an open skull and a trial about which almost nothing is known**. The TIME chain confirmed shortly after: the device allows the person to communicate via phone or computer.

The sequence matters more than the headline. First the loud announcement, then the confirmation, then the documentary silence. In between, an industry advancing by tweet while the fine print of the trial remains closed.

What the Announcement Confirms and What It Leaves Unanswered

Reuters dated a piece from Washington on February 2nd as uncomfortable: **Musk's statements generated more questions than answers** about a trial with a device considered high-risk. Four brain implant experts consulted by the agency pointed out the obvious: Neuralink is not required to disclose basic details of its trial, not even the center where the surgeries are performed.

In other words, there is an implant confirmed by the company owner himself and virtually nothing verifiable around it. The detection of neural spikes cited as an initial result is, in neurotechnology jargon, equivalent to checking that the cable carries a signal. Nothing more. And nothing less, because until two years ago that only existed in monkeys.

China Already Publicized Its Own Brain Implant in October

Right after Musk's announcement, the Chinese propaganda machinery came forward with the merits of an implant that, according to its account, **had already been performed in October**. The temporal coincidence is no accident: Beijing has spent years placing neurotechnology in its showcase of national achievements and competes for the same cutting-edge narrative.

The relevant detail is not who arrived first, but that the race already has two sprinters and no referee. When the regulatory framework is opaque on both sides, the question ceases to be technical and becomes geopolitical: who sets the standard for a device connected directly to a person's nervous system.

Planned Obsolescence Inside the Skull

The most repeated argument against it has nothing to do with science, but with warranty. A brain implant is not changed like a mobile phone: **your body does not regenerate the tissue surrounding the device** and there is no second-hand market for the cerebral cortex. If the company closes, if the model becomes obsolete, or if the firmware stops updating, the user is left with scrap soldered to their head.

The case of the man who presented himself as the first real cyborg in history thanks to an ocular implant is recalled, and whose outcome is used here as a warning. Dependence on a manufacturer maintaining the device drivers is, those who have closely trinc the sector point out, the same problem that already exists with any connected gadget, multiplied by the impossibility of throwing it away.

Reading the Brain Without a Chip: The Cap and the $173 Kit

There is a second path that does not require surgery and may be the most uncomfortable. External reading devices, such as caps with electrodes, are clinically safer as long as they only read signals. Socially, however, they open a worse door: **they can read your mind without having implanted anything in you**. Today the challenge is isolating the signal from electromagnetic noise; tomorrow, it is suggested, routine recording of brain activity could be done remotely with other functional scanning techniques, deeper and with better resolution.

For example, a storefront button: a home neuronal reading kit for **$173**, including cockroaches. If you already have them at home or nearby, you save $13. It is a proof of concept, not a Neuralink, but it demonstrates where technology is becoming cheaper.

---

The Zuckerberg Derivative and the Closure No One Signs

The conversation drifted, as usual, toward the owner of the platform where all this was written. In a hearing before the US Senate, several senators—including Josh Hawley, Lindsey Graham, and Marsha Blackburn—reproached Mark Zuckerberg that his company had not acted against the exploitation of minors on its networks. The accusations were launched in parliament and without a judicial ruling in between, but the contrast was served: the chip that does not yet exist is discussed, while tiptoeing around the algorithm that already works.

And there the analysis gets stuck. With the trial under lock and key, without a published center or accessible clinical data, there is no way to distinguish whether this is a therapy for paralyzed people or the first chapter of a subscription model installed in the nervous system. The announcement is made. Verification is pending.